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Acute on chronic liver failure (ACLF) is currently recognized as a specific entity characterized by acute
deterioration of liver function in the context of compensated or even decompensated, but hitherto stable,
cirrhosis. Worsening of liver function and subsequently of other end-organs occurs rapidly and follows a
precipitating event that directly or indirectly affects liver function. Available data indicate that ICU
mortality for ACLF ranges from 35% to 89% and in-hospital mortality ranges from 43% to 88%. Patient
outcome is not simply determined by the severity of liver disease. Indeed, the development and degree
of end-stage organ failure represents the main determinant of outcome in ACLF patients. The patho-
physiology of ACLF may be approached with the PIRO concept employed for sepsis (Predisposition,
Infection/Inflammation, Response, Organ Failure). According to this approach, Predisposition is indicated
by the severity of cirrhosis, Injury by nature/severity of the precipitating event(s), and the severity of
inflammation and risk of infection express the patient’s Response to injury. Finally, the extent of Organ
failure is responsible for prognosis of ACLF patients. Current medical therapy involves management of
the precipitating event, support end-organs and prevention/treatment of complications, until the
eventual recovery of liver function. If medical treatment fails, transplantation is the only option in eli-
gible patients. Characterization of the syndrome, definition of pathophysiological mechanisms, and
improvement of patient management, currently call for ample efforts.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Liver failure can develop acutely in the absence of pre-existing
liver disease (acute liver failure, ALF), in the presence of known
or unknown chronic liver disease (acute on chronic liver failure,
ACLF), or chronically, as decompensation of pre-existing end-stage
liver disease (Table 1). In recent years, ACLF has been increasinglyute on chronic liver failure;
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All rights reserved.recognized as a specific entity characterized by acute deterioration
of liver function in the context of compensated or even decom-
pensated, but hitherto stable, cirrhosis. Worsening of liver function
and subsequently of other organs occurs over a period of a few
weeks and follows a precipitating event. This event may directly
(e.g. drug- or alcohol-induced liver injury) or indirectly (e.g. sepsis,
portal hypertension-related bleeding) affect liver function. The
clinical features of ACLF imply rapid disease progression, the need
for multiple organ support and poor short- and medium-term
prognosis.1 However, a clear definition of ACLF is currently lack-
ing, and some uncertainties emerge, as this term is being used by
clinicians to define different conditions. Two consensus confer-
ences elaborated a definition for this syndrome. The first definition
of ACLF was provided by the AsiaePacific Association for the Study
of Liver Disease (APASL), as an ‘acute hepatic insult manifesting as
jaundice and coagulopathy, complicated within 4 weeks by ascites
and/or encephalopathy in a patient with previously diagnosed or
undiagnosed chronic liver disease’.2 Subsequently a second defi-
nition emerged from an EASL-AASLD single topic symposium,
where ACLF was defined as an ‘acute deterioration of pre-existing
chronic liver disease, usually related to a precipitating event
and associated with increased mortality at 3 months due to
multi-system organ failure’.3 The second definition, if not stated
Table 1
Comparison of end-stage liver disease and ACLF.
Present in both conditions Unique to ACLF





to cirrhotic patients with
similar MELD scores
Abbreviations: ACLF, acute on chronic liver failure; MELD, model of end stage liver
disease.
Table 3
End organs failure according to SOFA score.
Liver failure will be defined by a SOFA sub-score of 4
Respiratory failure by a sub-SOFA score 3 or requirement for mechanical
ventilation
Haematologic failure by a sub-SOFA sub-score of 4 and/or INR >2.5
Cardiovascular failure by a sub-SOFA score 2 (i.e. the use of vasopressors)
Neurologic failure by a sub-score 3 (based upon the West Haven criteria) or
requirement for endotracheal intubation to prevent aspiration pneumonia
Renal failure by a sub-SOFA score 2 or requirement for renal-replacement
therapy
Abbreviations: SOFA, sequential organ failure assessment; INR, international nor-
malized ratio.
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of the syndrome, definition of pathophysiological mechanisms, and
improvement of patient management, currently call for ample
efforts. This review focuses on recently acquired concepts related to
these various aspects. The pathophysiology of ACLF may be
approached with the PIRO concept employed for sepsis (predis-
position, infection/inflammation, response, organ failure).4
According to this approach, predisposition is indicated by the
severity of cirrhosis, injury by nature/severity of the precipitating
event(s), and the severity of inflammation and risk of infection
expressed in the patient’s response to injury. Finally, the extent of
organ failure is responsible for the prognosis of ACLF patients.
Categorization of patients with PIRO allows for a definition of
therapeutic intervention and prognosis at different levels.
2. Epidemiology, clinical scenario and prognosis (P)
Limited data are available concerning ACLF epidemiology. Data
obtained in a US patient sample, analysed in a EASL-AASLD single
topic symposium on the management of critically ill cirrhotic
patients in the intensive care unit (ICU),3 reported in-hospital
mortality of 53% and mean hospitalization length of 14 days for
ACLF. Prognostic factors predicting the outcome in patients with
ACLF are currently under evaluation. In ACLF, two simultaneous
insults are operating, acute and chronic. The degree of each injury is
variable, with a prominent role for either type. Whether the
prognosis of the patient depends on the degree of acute or chronic
injury, or both, is still not well defined (Table 2). Accumulating
evidence indicates that scoring systems simply addressing the
severity of liver disease, such as the Child-Pugh5 or the Model of
End Stage Liver Disease (MELD) scores,6 are not adequate in com-
parison to systems also evaluating extra-hepatic organ dysfunction
such as the Sequential Organ Failure Assessment (SOFA) (Table 3)7
or the Acute Physiology, Age and Chronic Health Evaluation
(APACHE)8 scores.9 Available data indicate that ICU mortality for
ACLF ranges from 35% to 89% and in-hospital mortality ranges from
43% to 88%,10e29 (for a comprehensive list of references see Ref. 9).
Although different criteria were employed in patient selection and
follow-up, a careful evaluation of these data demonstrates that
patient outcome is not merely determined by the severity of liverTable 2
Grades of ACLF.
ACLF-1: Renal failure or a non-renal organ failure associated with creatinine 1.5
e2 mg/dL and/or grade IeII encephalopathy;
ACLF-2: 2 organ failures
ACLF-3: 3 organ failures
ACLF-4: 4e6 organ failures
From R.Moreau et al., Diagnosis, prevalence, and prognosis of acute-on-chronic liver
failure (ACLF): results of the EASL-chronic liver failure (CLIF) consortium CANONIC
study. Abstract 1404, International Liver Congress 2012.
ACLF, acute on chronic liver failure.disease as expressed by conventional scoring systems (such as the
Child-Pugh score), while the development and degree of end-stage




The precipitating event may directly affect and worsen liver
function such as in the case of drug-induced liver injury, alcoholic
hepatitis, superimposed viral hepatitis, vascular diseases (mainly
portal vein thrombosis or Budd-Chiari syndrome) and ischaemic
hepatitis. Alternatively an extra-hepatic event may indirectly
induce decompensation (portal hypertension-related bleeding,
surgery, infection or trauma). Nonetheless, in a substantial pro-
portion of patients no precipitating event can be identified. Survival
of patients with bleeding related to portal hypertension can be
improved by early administration of antibiotics or by insertion of a
transjugular intrahepatic portosystemic shunt (TIPS), which is
indicated in actively bleeding Child Pugh class B patients and in
patients with advanced liver disease30,31 because cardio-
pulmonary events and the decline in hepatocellular function that
follows failure to control bleeding and/or early rebleeding were
prevented. Early antiviral therapy in patients acutely infected with
HBV in the setting of pre-existing chronic liver disease prevents
decompensation and improves survival.32
In patients undergoing surgery, the most relevant predictors of
post-operative mortality were severity of liver disease as indicated
by the MELD score, age, and the American Society of Anesthesiol-
ogists (ASA) score.33 It is conceivable that an altered patient
response to direct or indirect injury implies an unregulated
inflammatory response and immune dysfunction leading to
increased susceptibility to infection and ultimately causing ACLF.
This sequence of events defines a stereotyped common cascade
unifying diverse precipitating injuries/events.34
3.2. Inflammation and infection (R)
The pivotal role of a systemic inflammatory response (SIRS) in
ACLF emerges by its association with more severe encephalopathy,
infections, renal failure and poor outcome.34e36 Elevated levels of
multiple pro- and anti-inflammatory cytokines have been reported
in patients with ACLF, including tumour necrosis factor (TNF)-a,
sTNFaR1, sTNFaR2, interleukin (IL)-2, IL-2R, IL-6, IL-8, IL-10, and
interferon (IFN)-g.37,38 Although interference with these or other
cytokine systems could be considered an appealing therapeutic
strategy, only limited data are available. Moreover, the use of anti-
TNF-a in patients with alcoholic hepatitis has been associated with
an increased risk of infection and greater mortality rates.39,40













Fig. 2. The liver and other organs in acute on chronic liver failure (ACLF). CNS, central
nervous system; HE, hepatic encephalopathy; HRS, hepatorenal syndrome.
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the possible pathogenic role of this condition.
Bacterial infections in cirrhosis are common, particularly in
decompensated patients, and their occurrence increases mortality
by two- to four-fold.43 About 40e50% of patients with ACLF present
an infection at hospital admission and an additional 20e40% will
develop nosocomial infections. The mortality rate for severe bac-
terial infection in cirrhotic patients is about 60e100%.43e47 There-
fore, strict surveillance and repeated cultures are mandatory.
Careful use of indwelling devices, including urinary catheters, and
prompt prophylaxis or treatment of infections remain the corner-
stones of patient management.
Several causes account for the increased susceptibility of these
patients to bacterial infections. Liver dysfunction leads to several
abnormalities of defence mechanisms, as both humoral and cell-
mediated immunity are depressed. Therefore SIRS may lead to
immune dysregulation, predisposing to bacterial translocation and
infection, that in turn will further aggravate a pro-inflammatory
response.48 This vicious cycle ultimately results in sepsis, renal fail-
ure, bleeding or rebleeding, hepatic encephalopathy and death.49e53
Identification of biomarkers that predict susceptibility to infections
could in the future allow for the stratification of patients in clinical
categories with different risks, and therapy could be individualized.
Along these lines, neutrophil dysfunction in ACLF seems reversible
and probably due to circulating endotoxin.50 Interestingly prelimi-
nary data support a role for modulation of enteric microflora in the
recovery of neutrophil phagocytic capacity52 (Fig. 1).
3.3. Liver and other end-organs in ACLF (O)
Although liver damage is the initiating event in ACLF, its
occurrence triggers an involvement of other extrahepatic systems
that eventually condition the prognosis of the patient (Fig. 2).
3.4. Liver
Jaundice is considered an essential sign for the diagnosis of
ACLF. Various authors have used different cutoff levels of bilirubin,
















Fig. 1. Precipitating events in ACLF. Note that SIRS may even occur in the absence of
injury. Infection and sepsis are mainly related to spontaneous bacterial peritonitis,
pneumonia, urinary tract infection and skin infection. SIRS, systemic inflammatory
response syndrome; PH, portal hypertension. Modified from Olson & Kamath Curr
Opin Crit care 2011,17:165.level greater than 5 mg/dL of serum bilirubin was suggested in the
APASL consensus recommendations.2 Coagulopathy was defined by
APASL as a INR >1.5 or prothrombin activity less than 40%.
An early biopsy may help in understanding the mechanisms
involved and improve patient management (see liver histology in
ACLF). Indeed, ACLF due to a non-specific injury such as variceal
bleeding or bacterial infection is thought to cause different effects
other than direct injury such as the ones caused by drugs, toxins or
superimposed hepatitis. Recent evidence has highlighted the
importance of bilirubinostasis and SIRS as early markers to allow
identification of high-risk patients among those with acute dete-
rioration of alcoholic cirrhosis and resultant ACLF. Moreover, bilir-
ubin levels were strongly associated with an increased risk of
subsequent infection.58,59
Liver inflammationmarkedly influences portal pressure, a major
complication of cirrhosis and a critical determinant of prognosis,
and superimposed alcoholic hepatitis in patients with alcoholic
cirrhosis is a prototypical example of ACLF. In this context, exper-
imental studies indicate that TNF-a could play an important role in
the development of portal hypertension in alcoholic hepatitis.
Indeed, anti TNF-a therapy has been reported to reduce portal
pressure in patients with severe alcoholic hepatitis and cirrhosis.60
Several lines of evidence suggest that gut-derived endotoxaemia
plays a pivotal role in the pathogenesis of portal hypertension, and
therefore have a role in the pathogenesis of ACLF.61 In fact, modu-
lation of gut flora by antibiotics administration62,63 or endotoxin
neutralization with high density lipoproteins64 have been asso-
ciated with the reduction of portal pressure. Moreover, reactive
oxygen species also contribute to increase portal pressure, reducing
the availability of intra-hepatic nitric oxide (NO),65 and resulting in
increased intra-hepatic resistance to blood flow. Along these lines,
hepatic eNOS activity has been shown to be reduced in the context
of cirrhosis with superimposed inflammation.66,67 The liver also
plays a prominent role in the metabolism of asymmetric dimethyl-
L-arginine (ADMA), an endogenous inhibitor of nitric oxide syn-
thase. Hepatocellular damage is a main determinant of elevated
ADMA concentrations.68e72 Moreover, dysfunction of the cyclic
GMP system has been indicated as an additional mechanism
leading to reduced response to nitric oxide in cirrhotic livers.
Interestingly, phosphodiesterase-5 inhibitors such as sildenafil,
which increase cGMP, have been shown to have a beneficial effect
on intra-hepatic resistance.73
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Acute kidney injury is a frequent and important feature of ACLF,
as it is associated with poor prognosis.11e13,17,42,58,74,75 In general,
changes in renal haemodynamics occur early in cirrhosis and cul-
minate in a circulatory dysfunction that characterizes hepatorenal
syndrome (HRS). HRS is characterized by a massive splanchnic
vasodilatation, which reduces arterial blood pressure and leads to
extreme renal vasoconstriction, impaired cardiac function and
marked activation of the main vasoconstrictive systems76e78
(Table 4).
Hyperdynamic circulation is essential to maintain central blood
volume and renal perfusion in cirrhosis. When cardiac output
decreases, effective hypovolaemia is further enhanced, leading to
additional recruitment of endogenous vasopressor systems fol-
lowed by worsening of renal hypoperfusion and HRS. The mecha-
nisms leading to decreasing cardiac output remain largely
unknown, but SIRS has been suggested to be involved (see systemic
haemodynamics and cardiac dysfunction). Gold standard treat-
ments for HRS, which are directed to the restoration of arterial
effective blood volume, are unsuccessful in 54% of patients,79 sug-
gesting that in these patients different factors contribute to the
development of renal dysfunction. Moreover, in 30e40% of cirrhotic
patients with renal failure bacterial infection, e.g. spontaneous
bacterial peritonitis, is the leading cause.77
The role of inflammation and/or oxidative stress in renal failure
associated with ACLF is highlighted by the benefit of anti-
inflammatory agents such as albumin, pentoxifylline or N-ace-
tylcyteine, which decreased the risk of renal dysfunction in patients
with alcoholic hepatitis.80,81 In ACLF, both prerenal and renal causes
are involved in the pathogenesis of acute renal failure. Prerenal
factors are generally associated with renal hypoperfusion, which
may be associated with intravascular volume depletion (haemor-
rhage, renal and gastro-intestinal fluid loss). In other cases, a full-
blown HRS express the type of kidney damage in the presence of
marked deterioration of effective arterial blood volume. Most
intrarenal causes are related to ischaemic acute tubular necrosis
due to renal hypoperfusion.
Availability of urinary biomarkers in clinical practise may allow
early diagnosis of renal impairment and the discrimination
between functional and inflammatory causes. Markers of tubular
injury such as kidney injury molecule-1 and alpha glutathione S-
transferase or markers of inflammation such as NAG, NGAL, FABP,
and IL-1882 appear to be promising and will deserve further
evaluation.
3.6. Brain
Metabolic encephalopathies refer to alterations of the brain’s
integrated activity in the absence of structural abnormalities.83
Clinical manifestations vary from mild executive dysfunction or
agitated delirium to deep comawith decerebration. EncephalopathyTable 4
Diagnostic criteria for the hepatorenal syndrome.
 Cirrhosis with ascites
 Serum creatinine above 1.5 mg% (>1.33 mM)
 No improvement of serum creatinine (decrease to a level of 133mmol/L) after
at least 2 days with diuretic withdrawal and volume expansion with albumin.
The recommended dose of albumin is 1 g/Kg of bodyweight per day up to
a maximum of 100 mg/day
 Absence of shock
 No current or recent treatment with nephrotoxic drugs
 Absence of parenchymal kidney disease as indicated by proteinuria >
500 mg/day, microhaematuria (>50 red blood cells per high power field)
and/or abnormal renal ultrasonographymay represent a manifestation as well as a precipitating factor of
ACLF. From a pathophysiological perspective, brain swelling is an
important feature of ACLF.84e87 Ammonia is thought to play a key
role in the development of hepatic encephalopathy (HE) but no
direct relationship between the severity of hyperammonaemia and
HE has been demonstrated.88 The current view is that a synergy
between chronic increase in ammonia and inflammation related to
an acute hepatic insult facilitate the development of brain oedema.
The mechanism is likely related to generation of cytokines in the
brain, increased iNOS expression, oxidative stress and formation of
nitrated protein adducts.87,89
The most common clinical entities observed in decompensated
cirrhotic patients are hepatic and hyponatraemic encephalopathy
and they may even co-exist.90 Mortality rate in ICU was 10% in
patients with isolated encephalopathy and 80% in thosewith failure
of other organs.91 In these patients airway protection represents a
priority, and aspiration pneumonia and acute respiratory failure are
major complications of encephalopathy.
3.7. Systemic haemodynamics and cardiac dysfunction
Portal hypertension associated with cirrhosis is initiated by an
increase in intrahepatic vascular resistance, related both to fibrosis
and to increased intrahepatic vascular tone. The resulting increase
in splanchnic blood flow in turn gives rise to a hyperdynamic sys-
temic state. The increased cardiac output observed in this situation
is mainly due to a vasodilated splanchnic bed but paradoxically,
the blood flow in other organs, such as kidneys or the brain is
decreased.92
Circulatory failure in ACLF resembles severe sepsis and is typi-
cally characterized by an exacerbated hyperdynamic state with the
inability to obtain adequate perfusion pressure despite volume
expansion and large doses of inotropes, with subsequent appear-
ance of lactic acidosis.93e97 Indeed, unlike decompensated cir-
rhosis, where cardiac output remains elevated, in ACLF a drop in
cardiac output may be observed despite splanchnic vasodilation
and both systolic and diastolic function may become affected.
Cardiac dysfunction in ACLF, as well as in sepsis, is related to
increased TNF-a and nitric oxide, and decreased cortisol levels,98
resulting in further vascular dilatation and decreased sensitivity
to vasoconstrictors. Cortisol (see hepato-adrenal axis) is reduced in
more than 50% of patients affected by chronic liver disease and
concomitant sepsis, resulting in adrenal insufficiency.98e100 Car-
diovascular collapse in ACLF is associated with increased mortality,
especially in patients who present with other end-organ dysfunc-
tion and particularly renal failure.94 Therefore, is crucial to properly
follow cardiac function to guide fluid replacement and inotropic
support.
3.8. Coagulation
Regardless of abnormal routine coagulation tests, thrombin
generation is normal in compensated or “stable decompensated”
cirrhotic patients, due to a rebalancing of pro- and anti-coagulant
factors that seldom leads to hypercoagulation, providing that pla-
telet count is ‘adequate’, i.e. >50,000/uL. The prophylactic use of
blood products, even in the context of variceal bleeding is no
evidence-based and therefore empirical, and no effect of
recombinant factor VIIa has been shown.101 Moreover, normal-
ization of coagulation parameters is difficult to achieve and this
practise could provoke transfusion-related acute lung injury, vol-
ume excess and other transfusion-associated reactions. However,
endogenous low-molecular weight heparinoids are detected in
cirrhotic patients with sepsis, and disappear with resolution of
infection.46 Along these lines, administration of antibiotics in
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mortality.102 Major coagulation abnormalities described in ACLF
include increased fibrinolysis and defective platelet function.103
There is an unmet need for more comprehensive coagulation
tests to guide correction of coagulation dysfunction on an indi-
vidual basis.
3.9. Hepato-adrenal axis
Development of adrenal insufficiency worsens the prognosis of
cirrhotic patients with severe sepsis. As stated above, this disorder
has been reported in a considerable fraction (51e68%) of patients
with cirrhosis and severe sepsis, and particularly in those with
haemodynamic instability and more advanced liver disease as
expressed by MELD or Child-Pugh scores. Preliminary data indicate
that administration of hydrocortisone in this setting may improve
circulatory function.98
4. Portal pressure measurement in ACLF
ACLF is an acute event on an underlying liver disease and hence
portal pressure is thought to differ from that in patients with
compensated and even decompensated cirrhosis. Kumar et al.104
demonstrated that patients with small varices and lower hepatic
vein pressure gradient (HVPG) have a higher chance of recovery
after the acute insult settles down. Conversely, patients with large
varices or high HVPG have a poor prognosis following ACLF.
5. Liver histology in ACLF
Histologic data in ACLF are scarce, since it is not easy to obtain a
liver specimen in these often very sick patients, and thus the need
for a liver biopsy should be individualized. The transjugular
approach is relatively safe in these patients and allows simulta-
neous evaluation of systemic haemodynamic and HVPG. Liver
biopsy may provide information on the severity of the underlying
liver disease, and may also be useful in identifying the etiology of
the acute injury.
No histologic features are considered pathognomonic of ACLF.
Single centre data105 discriminate two patterns with different
prognosis: pattern I, characterized by hepatocyte ballooning,
rosette formation, cellular cholestasis, variable interface activity
and fibrosis; pattern II, with marked ductular proliferation, coarse,
inspissated bile plugs, foci of confluent/bridging necrosis, eosino-
philic degeneration of hepatocytes, higher stage of fibrosis and
variable activity. Pattern II was associated with a much worse
prognosis.
6. Management of ACLF
Current medical therapy involves management of the precip-
itating event, support end-organs and prevention/treatment of
complications, until the eventual recovery of liver function. If
medical treatment fails, transplantation is the only option in eli-
gible patients. However, cadaveric organ shortage strongly limits
this possibility, and alternative methods to support liver function
are currently being investigated. Intensive care management of
patients with ACLF is beyond the scope of this review. Otherwise,
the main principles of multiple organ support have to be employed
to allow treatment of acute injury and liver function recovery.
6.1. Liver transplantation
There is a paucity of data on liver transplantation in ACLF, even if
this represents the only definitive therapy for patients who do notimprove with supportive measures to multiple organs. Haemody-
namic instability and the need for high-dose inotropes, raised
intracranial pressure and reduction in cerebral perfusion pressure,
and the presence of severe bacterial and/or fungal infections make
patients often unsuitable to undergo transplantation. Therefore the
timing is crucial as patients with ACLF may have a narrow window
of opportunity. Following this line, living-donor transplantation
may be an attractive option. Encouraging results are reported from
South-East Asia in patients with ACLF due to re-activation of hep-
atitis B virus infection. Indeed, an 80% survival at 5 years was
reported in these patients.106 Bahirwani et al.107 also showed that
ACLF was not an independent predictor of post-transplant mor-
tality, arguing that this may be a good indication for trans-
plantation. Nevertheless, in many centres there is no prioritized
organ allocation for ACLF patients, due to scarcity of data and a
supposedly higher short-term mortality. A better understanding of
pathogenesis and natural history, and improvement in multiple
organ support and in the prevention of complications will allow
ACLF to be incorporated as a possible new indication for high
urgency allocation.
6.2. Liver support devices
The role of hepatotoxins in the development of ACLF provides a
rationale for the use of extracorporeal liver support systems. In
principle, liver-assisting devices aim to provide detoxification func-
tions to patients with ACLF, until liver function eventually recovers.
Nonetheless, even if this approach is safe andwell tolerated, devices
failed to demonstrate any survival benefit in randomized studies.108e
110 Twomajor types of liver support systems have been investigated,
acellular devices such as albumin dialysis and plasma-exchange/
diafiltration (mainly MARS and Prometheus), and bio-artificial liv-
ers, which incorporate cells from human or animal sources, or
immortalized cells. Preliminary data indicate a possible beneficial
effect in ACLF induced by HBV reactivation.111 The best studied liver
support devices are the Molecular Adsorbent Recirculating System
(MARS) and Prometheus devices, which are based on the principle of
albumin dialysis.112 Indeed, albumin exerts a number of functions
besides its oncotic properties. These devices may remove inflam-
matory molecules, reduce NO and improve systemic and hepatic
haemodynamics.109,113,114 Interestingly Prometheus showed a pos-
sible benefit in the sub-group of patients with a MELD score of >30
and in those with hepatorenal syndrome.109
6.3. Cell-based therapies
The therapeutic use of several types of cells has been hypothe-
sized to improve ACLF. In a recent study, Garg et al. tested the
possibility that mobilization of bone marrow-derived stem cells
with granulocyte colony-stimulating factor could promote hepatic
regeneration.115 Treatment with this cytokine resulted in a sig-
nificantly higher survival and improvement of liver function
parameters. These intriguing results await confirmation from dif-
ferent groups and different geographical areas.
6.4. Use of antivirals in ACLF
Spontaneous or iatrogenic (immunosuppression) flares of
inflammation are frequently observed in chronic hepatitis B. Anti-
viral therapy should be immediately initiated in patients with ACLF
related to re-activation of hepatitis B or acute infection in the
context of a different chronic liver disease. In general, drugs with
high potency and a high genetic barrier such as entecavir or teno-
fovir should be preferred in view of the long term need for viral
suppression.2
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ACLF is a devastating independent clinical syndrome with high
mortality. ACLF follows a precipitating event and is defined as an
acute and rapid worsening of liver function accompanied by sub-
sequent multiple end-organ failure in a patient with previously
compensated or reasonably compensated liver disease. The mor-
tality of ACLF is known to be high in inpatients (>50%), although no
long-term data are available. In ACLF patients, a concept similar to
the PIRO concept in sepsis (predisposition, infection/inflammation,
response, organ failure) might be useful in describing the patho-
physiology and clinical categories of this disorder. The patho-
physiology of ACLF relates to an altered response to injury, resulting
in an imbalanced inflammatory reaction and immune dysfunction
leading to an increased susceptibility to infection. Management of
the precipitating injury, multiple organ support and prevention and
treatment of complications are the mainstay when dealing with
ACLF patients. The liver transplant community will need to be more
engaged to define which ACLF patients are better candidates for
transplantation, and to define new allocation policies. Finally, a
better definition of this clinical scenario is needed, possibly with
the use of new biomarkers that allow development of new drugs
and devices.Conflicts of interest
None declared.References
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